Publicaciones en las que colabora con Daniel Castellano-Gauna (13)

2024

  1. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

2022

  1. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

  2. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

2021

  1. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  2. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

    European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091

2019

  1. Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study

    Medical Oncology, Vol. 36, Núm. 3

2018

  1. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

    Clinical Genitourinary Cancer, Vol. 16, Núm. 6, pp. e1133-e1139

  2. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653

2009

  1. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

    Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812